Acetylcysteine

Articles · Lactation Safety Information · New Medicines ·

77731008

Articles

Lactation Safety Information

For ophthalmic use

For ophthalmic use

New Medicines

Chronic obstructive pulmonary disease (COPD) and other respiratory tract disorders characterised by excessive, viscous mucus - adjunctive therapy

Information

New formulation
Ennogen Healthcare

Development and Regulatory status

Launched
None
None
November 2017

Nov 17: Launched in the UK [4].


Aug 17: Plan to launch this month as a generic acetylcysteine effervescent tablet. Price for 20 tabs, £84.90 [3].


Jul 16: Approved in UK for adjunctive therapy of respiratory tract disorders characterised by excessive, viscous mucus, including COPD, in adults including elderly and adolescents 14 years [1].

Category

Mucolytic agent in an effervescent 600mg tablet formulation. Acetylcysteine is believed to break the disulfide bonds in mucoproteins and it depolymerizes DNA strands in purulent mucus.
In the UK, it is estimated that more than 3 million people currently have COPD, and an estimated 2 million people have COPD which remains undiagnosed [2].
Chronic obstructive pulmonary disease (COPD) and other respiratory tract disorders characterised by excessive, viscous mucus - adjunctive therapy
Oral

Evidence based evaluations

NACSYS · Bronchiectasis, bronchitis, emphysema, mucoviscidoses - use as a mucolytic in adults

Information

NACSYS
New formulation
Atlantic Pharma

Development and Regulatory status

Launched
Launched
November 2017

Nov 17: NACSYS list price is £5.50 for 30 x 600mg effervescent tablets.[4]


Nov 17: NACSYS effervescent tablets are available in the UK. They are licensed for use as a mucolytic in adults with respiratory disorders such as in bronchitis, emphysema, mucoviscidoses and bronchiectasis [1,2].

Category

Mucolytic. Each effervescent tablet contains 600 mg of acetylcysteine.
A large study across 640 general practices in the UK found prevalence in 2011 in men was 227 per 100,000, and 309 per 100,000 in women. Incidence was 32 per 100,000 person-years at risk. Prevalence was higher in women than in men, and higher in the older age groups (>60 years). It is estimated that around 1,000 people die each year from bronchiectasis in England and Wales [3]
Bronchiectasis, bronchitis, emphysema, mucoviscidoses - use as a mucolytic in adults
Oral

Evidence based evaluations